

**GU CY1B2 Antibody(C-term) Blocking peptide**  
**Synthetic peptide**  
**Catalog # BP7135b****Specification**

---

**GU CY1B2 Antibody(C-term) Blocking peptide - Product Information**Primary Accession [O75343](#)**GU CY1B2 Antibody(C-term) Blocking peptide - Additional Information****Other Names**

Guanylate cyclase soluble subunit beta-2, GCS-beta-2, GUCY1B2

**Target/Specificity**

The synthetic peptide sequence used to generate the antibody [AP7135b](/product/products/AP7135b) was selected from the C-term region of human GUCY1B2. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.

**Format**

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

**Storage**

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

**Precautions**

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

**GU CY1B2 Antibody(C-term) Blocking peptide - Protein Information****Name** GUCY1B2**Cellular Location**

Cytoplasm.

**Tissue Location**

Expressed in gastric signet ring cell carcinoma, but not in the normal stomach.

**GU CY1B2 Antibody(C-term) Blocking peptide - Protocols**

Provided below are standard protocols that you may find useful for product applications.

- [Blocking Peptides](#)

**GU CY1B2 Antibody(C-term) Blocking peptide - Images**

**GUCY1B2 Antibody(C-term) Blocking peptide - Background**

Nitric oxide-sensitive guanylyl cyclase is a heterodimeric enzyme consisting of an alpha and a beta subunit. The enzyme converts GTP into the second messenger cGMP and plays a major role in the cardiovascular system as a receptor for nitric oxide. Unlike other guanylyl cyclases, GUCY1B2 contains an 86-amino acid C-terminal extension with a consensus sequence for isoprenylation/carboxymethylation.

**GUCY1B2 Antibody(C-term) Blocking peptide - References**

Behrends, S., et al., Biochem. Biophys. Res. Commun. 271(1):64-69 (2000). Behrends, S., et al., Biochem. Pharmacol. 59(6):713-717 (2000). Bellamy, T.C., et al., Proc. Natl. Acad. Sci. U.S.A. 97(6):2928-2933 (2000). Behrends, S., et al., Genomics 55(1):126-127 (1999). Yuen, P.S., et al., Biochemistry 29(49):10872-10878 (1990).